成功的合作使美国在 2022 年麻风疫情爆发期间增加了诊断检测。

IF 2.2 4区 医学 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Journal of Public Health Management and Practice Pub Date : 2024-10-25 DOI:10.1097/PHH.0000000000002024
Christina L Hutson, Julie Villanueva, Timothy Stenzel, Victoria A Olson, Noel Gerald, Rebecca McNall, Sean Courtney, Tricia Aden, Stacy Rager, Christina Egan, Patricia Blevins, Wendi Kuhnert, Whitni Davidson, Theodora Khan, Nicolle Baird, Chantal Kling, Susan Van Meter, Jasmine Chaitram, Reynolds M Salerno
{"title":"成功的合作使美国在 2022 年麻风疫情爆发期间增加了诊断检测。","authors":"Christina L Hutson, Julie Villanueva, Timothy Stenzel, Victoria A Olson, Noel Gerald, Rebecca McNall, Sean Courtney, Tricia Aden, Stacy Rager, Christina Egan, Patricia Blevins, Wendi Kuhnert, Whitni Davidson, Theodora Khan, Nicolle Baird, Chantal Kling, Susan Van Meter, Jasmine Chaitram, Reynolds M Salerno","doi":"10.1097/PHH.0000000000002024","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>The first case of mpox was detected in the United States in a Laboratory Response Network (LRN) laboratory at the Massachusetts Department of Public Health on May 17, 2022. Through previous years of smallpox preparedness efforts by the United States government, testing capacity in LRN laboratories across the United States utilizing the FDA-cleared Centers for Disease Control and Prevention (CDC) Non-variola orthopoxvirus (NVO) test was approximately 6000 tests weekly across the nation prior to the mpox outbreak. By early June 2022, the LRN laboratories had capacity to perform up to 8000 tests per week. As the outbreak expanded, cases were identified in every United States state, peaking at ~3000 cases per week nationally in August 2022.</p><p><strong>Objective: </strong>Although NVO testing capacity in LRN laboratories exceeded national mpox testing demand overall, LRN testing access in some areas was challenged and test expansion was necessary.</p><p><strong>Participants: </strong>CDC engaged with partners and select commercial laboratories early to increase diagnostic testing access by allowing these commercial laboratories to utilize the NVO test.</p><p><strong>Setting: </strong>The expansion of testing to commercial laboratories increased testing availability, capacity, and volume nationwide. This was the first time that CDC shared an FDA 510k-cleared molecular test with commercial laboratories to support a public health emergency.</p><p><strong>Design: </strong>Extensive efforts were made to ensure the CDC NVO test was used appropriately in the private sector and that the transfer process met regulatory requirements.</p><p><strong>Main outcome measures, results, conclusions: </strong>These novel methods to expand NVO testing to commercial laboratories increased national testing capacity to 80 000 mpox tests/week. Test volumes among these laboratories never exceeded this expanded capacity. The rapid increase in the nation's testing capacity, in conjunction and coordination with other public and private health efforts, helped to detect cases rapidly. These actions demonstrated the importance of highly functional and efficient public health and private sector partnerships for responding to public health emergencies.</p>","PeriodicalId":47855,"journal":{"name":"Journal of Public Health Management and Practice","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Successful Collaborations that Resulted in Increased U.S. Diagnostic Testing During the 2022 Mpox Outbreak.\",\"authors\":\"Christina L Hutson, Julie Villanueva, Timothy Stenzel, Victoria A Olson, Noel Gerald, Rebecca McNall, Sean Courtney, Tricia Aden, Stacy Rager, Christina Egan, Patricia Blevins, Wendi Kuhnert, Whitni Davidson, Theodora Khan, Nicolle Baird, Chantal Kling, Susan Van Meter, Jasmine Chaitram, Reynolds M Salerno\",\"doi\":\"10.1097/PHH.0000000000002024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Context: </strong>The first case of mpox was detected in the United States in a Laboratory Response Network (LRN) laboratory at the Massachusetts Department of Public Health on May 17, 2022. Through previous years of smallpox preparedness efforts by the United States government, testing capacity in LRN laboratories across the United States utilizing the FDA-cleared Centers for Disease Control and Prevention (CDC) Non-variola orthopoxvirus (NVO) test was approximately 6000 tests weekly across the nation prior to the mpox outbreak. By early June 2022, the LRN laboratories had capacity to perform up to 8000 tests per week. As the outbreak expanded, cases were identified in every United States state, peaking at ~3000 cases per week nationally in August 2022.</p><p><strong>Objective: </strong>Although NVO testing capacity in LRN laboratories exceeded national mpox testing demand overall, LRN testing access in some areas was challenged and test expansion was necessary.</p><p><strong>Participants: </strong>CDC engaged with partners and select commercial laboratories early to increase diagnostic testing access by allowing these commercial laboratories to utilize the NVO test.</p><p><strong>Setting: </strong>The expansion of testing to commercial laboratories increased testing availability, capacity, and volume nationwide. This was the first time that CDC shared an FDA 510k-cleared molecular test with commercial laboratories to support a public health emergency.</p><p><strong>Design: </strong>Extensive efforts were made to ensure the CDC NVO test was used appropriately in the private sector and that the transfer process met regulatory requirements.</p><p><strong>Main outcome measures, results, conclusions: </strong>These novel methods to expand NVO testing to commercial laboratories increased national testing capacity to 80 000 mpox tests/week. Test volumes among these laboratories never exceeded this expanded capacity. The rapid increase in the nation's testing capacity, in conjunction and coordination with other public and private health efforts, helped to detect cases rapidly. These actions demonstrated the importance of highly functional and efficient public health and private sector partnerships for responding to public health emergencies.</p>\",\"PeriodicalId\":47855,\"journal\":{\"name\":\"Journal of Public Health Management and Practice\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-10-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Public Health Management and Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/PHH.0000000000002024\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Public Health Management and Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PHH.0000000000002024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

背景:2022 年 5 月 17 日,马萨诸塞州公共卫生部的实验室响应网络 (LRN) 实验室检测到美国首例天花病例。通过美国政府前几年的天花防备工作,在天花疫情爆发前,美国各地的 LRN 实验室使用经美国食品和药物管理局(FDA)批准的美国疾病控制和预防中心(CDC)非病毒正痘病毒(NVO)检测工具的检测能力约为每周 6000 次。到 2022 年 6 月初,LRN 实验室的检测能力已达到每周 8000 次。随着疫情的扩大,美国各州都发现了病例,到 2022 年 8 月,全国最高峰达到每周约 3000 例:虽然 LRN 实验室的 NVO 检测能力总体上超过了全国的麻疹痘检测需求,但某些地区的 LRN 检测通道受到挑战,因此有必要扩大检测范围:疾控中心与合作伙伴和部分商业实验室及早接触,通过允许这些商业实验室使用 NVO 检测来增加诊断检测的可及性:将检测扩展到商业实验室提高了全国范围内的检测可用性、能力和数量。这是疾病预防控制中心首次与商业实验室共享美国食品及药物管理局(FDA)510k 批准的分子检测方法,以支持公共卫生突发事件:设计:为确保疾病预防控制中心的 NVO 检测在私营部门得到合理使用以及转让过程符合监管要求,我们做出了大量努力:通过这些新方法将 NVO 检测扩大到商业实验室,使全国的检测能力提高到每周 8 万次麻疹腮腺炎检测。这些实验室的检测量从未超过扩大后的检测能力。全国检测能力的迅速提高,与其他公共和私人卫生工作的配合和协调,有助于迅速发现病例。这些行动表明,在应对公共卫生突发事件时,公共卫生和私营部门必须建立功能强大、效率高的合作伙伴关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Successful Collaborations that Resulted in Increased U.S. Diagnostic Testing During the 2022 Mpox Outbreak.

Context: The first case of mpox was detected in the United States in a Laboratory Response Network (LRN) laboratory at the Massachusetts Department of Public Health on May 17, 2022. Through previous years of smallpox preparedness efforts by the United States government, testing capacity in LRN laboratories across the United States utilizing the FDA-cleared Centers for Disease Control and Prevention (CDC) Non-variola orthopoxvirus (NVO) test was approximately 6000 tests weekly across the nation prior to the mpox outbreak. By early June 2022, the LRN laboratories had capacity to perform up to 8000 tests per week. As the outbreak expanded, cases were identified in every United States state, peaking at ~3000 cases per week nationally in August 2022.

Objective: Although NVO testing capacity in LRN laboratories exceeded national mpox testing demand overall, LRN testing access in some areas was challenged and test expansion was necessary.

Participants: CDC engaged with partners and select commercial laboratories early to increase diagnostic testing access by allowing these commercial laboratories to utilize the NVO test.

Setting: The expansion of testing to commercial laboratories increased testing availability, capacity, and volume nationwide. This was the first time that CDC shared an FDA 510k-cleared molecular test with commercial laboratories to support a public health emergency.

Design: Extensive efforts were made to ensure the CDC NVO test was used appropriately in the private sector and that the transfer process met regulatory requirements.

Main outcome measures, results, conclusions: These novel methods to expand NVO testing to commercial laboratories increased national testing capacity to 80 000 mpox tests/week. Test volumes among these laboratories never exceeded this expanded capacity. The rapid increase in the nation's testing capacity, in conjunction and coordination with other public and private health efforts, helped to detect cases rapidly. These actions demonstrated the importance of highly functional and efficient public health and private sector partnerships for responding to public health emergencies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Public Health Management and Practice
Journal of Public Health Management and Practice PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
3.40
自引率
9.10%
发文量
287
期刊介绍: Journal of Public Health Management and Practice publishes articles which focus on evidence based public health practice and research. The journal is a bi-monthly peer-reviewed publication guided by a multidisciplinary editorial board of administrators, practitioners and scientists. Journal of Public Health Management and Practice publishes in a wide range of population health topics including research to practice; emergency preparedness; bioterrorism; infectious disease surveillance; environmental health; community health assessment, chronic disease prevention and health promotion, and academic-practice linkages.
期刊最新文献
Perceptions of Criticality and Frequency of Tasks by the Public Health Workforce, 2022. Real-Time Dashboard for Identifying Overdose Touchpoints in Indiana. Assessing Facility Readiness to Provide Equitable Birthing Care in New York State: A Baseline Survey. Training the Next Generation of Local Public Health Leaders: A Case Study of Community Health Organizers in Pennsylvania. Maintaining and Improving Virtual Call Centers for Public Health: The CUNY Recovery Corps Experience.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1